About Allomek Therapeutics
Allomek Therapeutics is a company based in Farmington (United States) founded in 2010 was acquired by Pasithea in October 2022. Allomek Therapeutics has raised $1.76 million across 3 funding rounds from investors including Pasithea and Connecticut Innovations. Allomek Therapeutics operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Farmington, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Allomek Therapeutics
Allomek Therapeutics has successfully raised a total of $1.76M across 3 strategic funding rounds. The most recent funding activity was a Seed round of $1.31 million completed in February 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Allomek Therapeutics
Allomek Therapeutics has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Pasithea and Connecticut Innovations.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital services for biotech, IT, and innovative sectors in Connecticut.
|
Locked | Locked | Locked | |
|
Pasithea is focused on developing treatments for neurological disorders.
|
Locked | Locked | Locked |
Investor details for Allomek Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Allomek Therapeutics
Investment portfolio details for Allomek Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Allomek Therapeutics
Detailed financials for Allomek Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Allomek Therapeutics Comparisons
Peer comparison for Allomek Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Allomek Therapeutics
Allomek Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
Detailed competitors of Allomek Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Allomek Therapeutics
Complete news archive for Allomek Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Allomek Therapeutics
Allomek Therapeutics was founded in 2010 and raised its 1st funding round 3 years after it was founded.
Allomek Therapeutics is headquartered in Farmington, United States.
Allomek Therapeutics is a funded company, having raised a total of $1.76M across 3 funding rounds to date.
Allomek Therapeutics was founded in 2010 and is based in Farmington, United States. Operations are conducted virtually through partnerships with contract research organizations. Focus is placed on the development of allosteric MEK inhibitors as targeted small molecule therapeutics for oncology. Preclinical testing is underway for multiple cancer indications, with emphasis on precision approaches in the biotechnology sector.
Allomek Therapeutics's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Allomek Therapeutics has 2 investors. Key investors include Pasithea, and Connecticut Innovations.